Dr. Carla Casu
Dr. Casu joined the Rivella lab while she was finishing her PhD in Italy in 2008. She is now focusing on developing new drugs for the treatment of disorders associated with abnormal iron metabolism and erythropoiesis. She characterized new drugs that mimic or increase hepcidin’s activity and reduce iron absorption and erythroid iron intake. These drugs are effective in improving the phenotype of mice affected by hemochromatosis, beta-thalassemia and polycythemia vera. As a result of her work, these compounds are now in clinical trials.